Micofenolato Mofetile Sandoz (Mycophenolate Mofetil)

Mycophenolate Mofetil blocks the enzyme inosine monophosphate dehydrogenase, which is essential for making guanosine nucleotides in lymphocytes. By limiting these nucleotides, the drug suppresses the proliferation of T and B cells, reducing the immune response that can damage transplanted organs or kidneys in lupus.

The dose of Mycophenolate Mofetil is individualized by the prescribing physician based on the transplant type, patient weight, renal function and other clinical factors. Patients should follow the exact regimen provided by their healthcare professional.

Mycophenolate Mofetil is classified as Pregnancy Category D, indicating evidence of fetal risk. It is generally contraindicated during pregnancy and should be stopped before conception. Breastfeeding is not recommended because the drug is excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with azathioprine, Mycophenolate Mofetil offers more selective inhibition of lymphocyte proliferation and often provides stronger protection against acute rejection. Unlike calcineurin inhibitors such as tacrolimus, it does not cause nephrotoxicity, but it may have a higher risk of gastrointestinal upset and bone‑marrow suppression.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging. Keep it away from moisture and direct sunlight. Do not refrigerate or freeze unless the manufacturer’s label specifically advises otherwise.

The medication is taken orally, usually with food or a light snack to reduce gastrointestinal irritation. It is available as tablets or capsules that should be swallowed whole with water; crushing or chewing is not recommended unless instructed by a pharmacist.

Serious risks include severe infections due to immune suppression, leukopenia or other blood‑cell abnormalities, liver injury, and potential fetal harm if taken during pregnancy. Patients should be monitored regularly for signs of infection, blood‑count changes and liver‑function abnormalities.

The drug is contraindicated in patients with known hypersensitivity to Mycophenolate Mofetil or any excipients, in pregnant women, and in individuals with severe uncontrolled infections. Caution is also advised for patients with significant renal or hepatic impairment.